Cargando…
Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumor Effect in Breast Cancer by Targeting Nrf2 Signaling Pathway
Triple-negative breast cancer (TNBC) has been clearly recognized as a heterogeneous tumor with the worst prognosis among the subtypes of breast cancer (BC). The advent and application of current small-molecule drugs for treating TNBC, as well as other novel inhibitors, among others, have made treatm...
Autores principales: | Li, Jing, Zhang, Jianchao, Zhu, Yan, Afolabi, Lukman O., Chen, Liang, Feng, Xuesong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179160/ https://www.ncbi.nlm.nih.gov/pubmed/37175972 http://dx.doi.org/10.3390/ijms24098265 |
Ejemplares similares
-
Brusatol, an NRF2 inhibitor for future cancer therapeutic
por: Cai, Sabrina J., et al.
Publicado: (2019) -
Brusatol
por: Hu, Shu-Zhi, et al.
Publicado: (2012) -
Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway
por: Xiang, Yukai, et al.
Publicado: (2018) -
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
por: Evans, Jonathan P., et al.
Publicado: (2018) -
The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers
por: Tian, Ziyin, et al.
Publicado: (2022)